Association of use of statins with progression of diabetic retinopathy: a randomized controlled trial at a tertiary care centre in Southern India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252025Keywords:
Diabetes, Diabetic retinopathy, Lipid lowering therapy, Retinal health, StatinsAbstract
Background: Diabetic retinopathy (DR) is a major microvascular complication of type 2 diabetes mellitus (T2DM) and a leading cause of vision impairment globally. Statins, beyond their lipid-lowering and cardiovascular benefits, may offer protective effects against DR by reducing inflammation, stabilizing endothelial function and modulating vascular endothelial growth factor (VEGF) expression. This study aimed to assess the impact of statin therapy on DR severity in patients with T2DM.
Methods: A randomized controlled trial was conducted at Government General Hospital, Srikakulam, between April 2024 and February 2025. A total of 120 patients with DR were enrolled and divided into two groups: those receiving statin therapy and those not on statins. DR severity was assessed using fundus examination findings and compared between the two groups.
Results: Among the 60 patients on statins, 62.2% had mild non-proliferative diabetic retinopathy (NPDR), while only 3.3% had proliferative DR (PDR) and 1.7% had diabetic macular edema (DME). In contrast, among non-statin users, only 18.2% had mild NPDR, while 29.1% had severe NPDR, 14.5% had PDR and 7.3% had DME. One patient also had vitreous hemorrhage.
Conclusions: Statin therapy appears to be associated with milder forms of DR in patients with T2DM. These findings suggest that statins may help slow DR progression, highlighting their potential as an adjunctive therapy for retinal protection in diabetes management.
Metrics
References
World Health Organization. Prevention of Blindness from Diabetes Mellitus: Report of a WHO Consultation in Geneva, Switzerland, 9-11 November 2005. Geneva: WHO. 2006.
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-39. DOI: https://doi.org/10.1056/NEJMra1005073
Reddy SV, Husain D. Panretinal photocoagulation: A review of complications. Semin Ophthalmol. 2018;33(1):83-8. DOI: https://doi.org/10.1080/08820538.2017.1353820
Kang EYC, Chen TH, Garg SJ, Sun CC, Kang JH, Wu WC, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2019;137(4):363-71.
Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22. DOI: https://doi.org/10.1016/S0140-6736(02)09327-3
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): A multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. DOI: https://doi.org/10.1016/S0140-6736(04)16895-5
Patel KK, Sehgal VS, Kashfi K. Molecular targets of statins and their potential side effects: Not all the glitter is gold. Eur J Pharmacol. 2022;922:174906. DOI: https://doi.org/10.1016/j.ejphar.2022.174906
Julius A, Hopper W. A non-invasive, multi-target approach to treat diabetic retinopathy. Biomed Pharmacother. 2019;109:708-15. DOI: https://doi.org/10.1016/j.biopha.2018.10.185
Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin epidemiologic study of diabetic retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98(8):1261-5. DOI: https://doi.org/10.1016/S0161-6420(91)32145-6
Vail D, Callaway NF, Ludwig CA, Saroj N, Moshfeghi DM. Lipid-lowering medications are associated with lower risk of retinopathy and ophthalmic interventions among United States patients with diabetes. Am J Ophthalmol. 2019;207:378-84. DOI: https://doi.org/10.1016/j.ajo.2019.05.029
Hermans MP, Fruchart JC. Reducing vascular events risk in patients with dyslipidemia: An update for clinicians. Therap Adv Chronic Dis. 2011;2(5):307-23. DOI: https://doi.org/10.1177/2040622311413952
Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol. 2004;137(4):675-82. DOI: https://doi.org/10.1016/j.ajo.2003.11.017
Priyadarshini P, Chogtu B, Bhandary SV, Kabirdev, Magazine R. Association of use of statins with progression of diabetic retinopathy at a tertiary care hospital in Southern India. J Curr Ophthalmol. 2022;34(2):234-40. DOI: https://doi.org/10.4103/joco.joco_70_21
Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: A systematic review and meta-analysis. Ophthalmology. 2015;122(9):1820-7. DOI: https://doi.org/10.1016/j.ophtha.2015.05.011
Kang EYC, Chen TH, Garg SJ, Sun CC, Kang JH, Wu WC, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2019;137(4):363-71. DOI: https://doi.org/10.1001/jamaophthalmol.2018.6399
Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet. 2007;370(9600):1687-97. DOI: https://doi.org/10.1016/S0140-6736(07)61607-9
Bloomgarden ZT. Diabetic retinopathy and diabetic neuropathy. Diabetes Care. 2007;30(3):760-5. DOI: https://doi.org/10.2337/dc07-zb03
Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56(1):1-11. DOI: https://doi.org/10.1016/S0168-8227(01)00341-2
Downloads
Published
How to Cite
Issue
Section
